Citius Pharmaceuticals, Inc. (CTXR) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on oncology, anti-infectives, and stem cell therapies. The company operates through its majority-owned subsidiary, Citius Oncology, Inc. (CTOR), which commercializes LYMPHIR (denileukin diftitox) for cutaneous T-cell lymphoma (CTCL). Commercial sales of LYMPHIR commenced in December 2025. The company also holds rights to Mino-Lok (anti-infective) and NoveCite (stem cell therapy).
Key Financial Metrics
| Metric | Six Months Ended Mar 31, 2026 | Six Months Ended Mar 31, 2025 |
|---|---|---|
| Revenue | $5,611,409 | $0 |
| Gross Profit | $4,493,323 | $0 |
| Gross Margin | 80.1% | N/A |
| Net Loss | $(37,503,635) | $(21,792,751) |
| Net Loss Per Share (Basic/Diluted) | $(1.34) | $(2.58) |
| Cash and Cash Equivalents (Mar 31, 2026) | $4,590,174 | $3,251,880 (Sep 30, 2025) |
| Working Capital | $(23,329,868) | $(16,980,267) |
| Accumulated Deficit | $(268,256,054) | $(238,804,129) |
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $5.6 million in revenue for the six months ended March 31, 2026, compared to zero in the prior year, driven by the commercial launch of LYMPHIR in December 2025.
- Operating Expenses: Total operating expenses increased significantly to $45.7 million (from $21.3 million). This was primarily due to a $19.7 million contract cancellation fee recorded in General and Administrative expenses following the termination of a contract manufacturing organization (CMO) agreement in February 2026 due to payment breaches.
- Amortization: Amortization of in-process research and development (IPR&D) for LYMPHIR began in December 2025, resulting in $2.3 million of expense for the six-month period.
- Non-Operating Income: The company recognized a one-time gain of $3.8 million from the sale of New Jersey net operating losses.
Outlook, Risks, and Subsequent Events
- Going Concern: The filing includes a "substantial doubt" regarding the company's ability to continue as a going concern. Management estimates cash resources will fund operations only through November 2026 without additional financing.
- Recent Capital Raises (Subsequent Events):
- April 24, 2026: Citius Pharma closed a registered direct offering raising approximately $5.0 million.
- May 5, 2026: Citius Oncology raised approximately $11.5 million via a warrant inducement exercise.
- May 5, 2026: Citius Oncology entered a loan agreement for up to $25.0 million, with $10.0 million funded immediately.
- Commercial Progress: LYMPHIR has achieved broad payer coverage (80% of covered lives) and initial shipments to Europe via Named Patient Programs. Positive top-line results were announced for investigator-initiated trials in DLBCL and gynecologic cancers.
- Manufacturing Risk: Following the CMO termination, the company is evaluating new suppliers but anticipates no immediate interruption in supply.
- Nasdaq Compliance: Both Citius Pharma and Citius Oncology received notices of non-compliance with Nasdaq minimum bid price rules ($1.00) and have 180-day compliance periods.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $16.5 million raised in April/May 2026 to cover the $23.3 million negative working capital and ongoing burn rate through November 2026.
- CMO Transition: Confirm the status of the new contract manufacturing agreement expected by June 30, 2026, to ensure uninterrupted LYMPHIR supply.
- Debt Obligations: Review the terms of the new $25 million loan facility (12.75% interest, secured by all assets) and the $17.65 million milestone payment due to Dr. Reddy's.
- Revenue Sustainability: Assess whether the initial LYMPHIR sales momentum can offset the high fixed costs and amortization expenses to achieve profitability.
- Dilution: Monitor the impact of the recent warrant exercises and new equity issuances on existing shareholder ownership.